Patents by Inventor Claudio Pietra

Claudio Pietra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250235442
    Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
    Type: Application
    Filed: February 21, 2025
    Publication date: July 24, 2025
    Applicants: Helsinn Healthcare SA, Anacardio AB
    Inventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
  • Publication number: 20250205216
    Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (1), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
    Type: Application
    Filed: June 2, 2022
    Publication date: June 26, 2025
    Applicants: Helsinn Healthcare SA, Anacardio AB
    Inventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
  • Publication number: 20240293388
    Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
    Type: Application
    Filed: May 2, 2024
    Publication date: September 5, 2024
    Applicant: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
  • Patent number: 12071421
    Abstract: Disclosed are compounds including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, useful in the prevention and/or treatment of diseases including emesis induced by chemotherapy. Also disclosed are methods of making a di-tert-butyl (chloromethyl) phosphate useful in the manufacture of such prodrugs by reacting a dialkylphosphate salt with an acid to obtain the corresponding ester of phosphoric acid, reacting the ester with a quaternary ammonium hydroxide base to form a monobasic salt, and reacting the monobasic salt with chloroiodomethane to form the corresponding chloromethyl dialkyl phosphate.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: August 27, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Publication number: 20240277688
    Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
    Type: Application
    Filed: June 2, 2022
    Publication date: August 22, 2024
    Applicants: Helsinn Healthcare SA, Anacardio AB
    Inventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
  • Patent number: 12005056
    Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 11, 2024
    Assignee: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
  • Patent number: 11976575
    Abstract: An organic Rankine cycle system with cascade cycles provided with a first organic Rankine cycle which operates at high temperature, in which a first organic working fluid carries out a heat exchange with a hot source fluid and a second organic Rankine cycle which operates at a temperature lower than the temperature of the first organic Rankine cycle and in which a second organic working fluid carries out a heat exchange with the same hot source. The evaporator of the first organic Rankine cycle is fed by the entire flow rate of the hot source fluid, while the evaporator and the preheater of the second organic Rankine cycle are fed by a first partial flow of the hot source fluid, the remaining second partial flow of the hot source fluid being used to partially carry out the preheating of the organic working fluid of the first organic Rankine cycle.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: May 7, 2024
    Assignee: TURBODEN S.P.A.
    Inventors: Mario Gaia, Roberto Bini, Claudio Pietra
  • Patent number: 11884646
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: January 30, 2024
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Patent number: 11802494
    Abstract: A cascade organic Rankine cycle plant comprising a hot source, at least a first high temperature organic Rankine cycle and a second low temperature organic Rankine cycle, said cycles comprising at least one preheater, at least one vaporizer, at least one turbine, at least one condenser, wherein the hot source first supplies a vaporizer of the high temperature cycle, then the vaporizer of the low temperature cycle and finally it is divided into two flows which supply a first preheater of the high temperature cycle and a preheater of the low temperature cycle. The first high-temperature organic Rankine cycle comprises a further vaporizer operating at an intermediate pressure between the vaporizer pressure of the high temperature cycle and the vaporizer pressure of the low temperature cycle.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 31, 2023
    Assignee: TURBODEN S.p.A.
    Inventors: Roberto Bini, Mario Gaia, Claudio Pietra
  • Publication number: 20230220789
    Abstract: An organic Rankine cycle system with cascade cycles provided with a first organic Rankine cycle which operates at high temperature, in which a first organic working fluid carries out a heat exchange with a hot source fluid and a second organic Rankine cycle which operates at a temperature lower than the temperature of the first organic Rankine cycle and in which a second organic working fluid carries out a heat exchange with the same hot source. The evaporator of the first organic Rankine cycle is fed by the entire flow rate of the hot source fluid, while the evaporator and the preheater of the second organic Rankine cycle are fed by a first partial flow of the hot source fluid, the remaining second partial flow of the hot source fluid being used to partially carry out the preheating of the organic working fluid of the first organic Rankine cycle.
    Type: Application
    Filed: May 26, 2021
    Publication date: July 13, 2023
    Applicant: TURBODEN S.P.A.
    Inventors: Mario GAIA, Roberto BlNl, Claudio Pietra
  • Publication number: 20230158007
    Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
    Type: Application
    Filed: March 14, 2019
    Publication date: May 25, 2023
    Applicant: Helsinn Healthcare SA
    Inventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
  • Publication number: 20220401463
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: March 21, 2022
    Publication date: December 22, 2022
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Publication number: 20220340541
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Application
    Filed: March 7, 2022
    Publication date: October 27, 2022
    Applicant: Helsinn Healthcare SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Publication number: 20220205370
    Abstract: A cascade organic Rankine cycle plant comprising a hot source, at least a first high temperature organic Rankine cycle and a second low temperature organic Rankine cycle, said cycles comprising at least one preheater, at least one vaporizer, at least one turbine, at least one condenser, wherein the hot source first supplies a vaporizer of the high temperature cycle, then the vaporizer of the low temperature cycle and finally it is divided into two flows which supply a first preheater of the high temperature cycle and a preheater of the low temperature cycle. The first high-temperature organic Rankine cycle comprises a further vaporizer operating at an intermediate pressure between the vaporizer pressure of the high temperature cycle and the vaporizer pressure of the low temperature cycle.
    Type: Application
    Filed: April 30, 2020
    Publication date: June 30, 2022
    Applicant: TURBODEN S.P.A.
    Inventors: Roberto BlNl, Mario GAIA, Claudio PIETRA
  • Patent number: 11312698
    Abstract: Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 11299472
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 12, 2022
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
  • Publication number: 20200399240
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 24, 2020
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Publication number: 20200299260
    Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
    Type: Application
    Filed: December 7, 2018
    Publication date: September 24, 2020
    Applicant: Helsinn Healthcare SA
    Inventors: Silvina GARCIA RUBIO, Mauro PERSEGHINI, Angelo GUAINAZZI, Claudio PIETRA, Claudio GIULIANO
  • Publication number: 20200262850
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 24, 2020
    Publication date: August 20, 2020
    Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
  • Patent number: 10717721
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 21, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella